Journal of Molecular Imaging & Dynamics
Open Access

Kolb HC

Publications

• Research Article
  Initial Experience of Monitoring Response of Breast Cancer to Bevacizumab-containing Chemotherapy using A New Integrin Specific PET Imaging Tracer [F-18]RGD-K5
  Author(s): Bahri S, Kain TS, Mehta RS, Herman J, Kuzucan A, Chen JH, Kolb HC, Walsh JC and Su MYBahri S, Kain TS, Mehta RS, Herman J, Kuzucan A, Chen JH, Kolb HC, Walsh JC and Su MY
  
  This study investigates the use of [F-18]RGD-K5, an integrin αvβ3 targeting PET tracer, in breast cancer patients receiving chemotherapy with bevacizumab (Avastin®). Two patients were analyzed: Subject-1 had metastatic breast cancers and Subject-2 had a primary cancer in the breast. The therapy regimen was weekly paclitaxel and carboplatin combined with bi-weekly bevacizumab. Each subject received 5 PET-CT scans: pre-treatment [F-18]RGD-K5 and [F-18]FDG, one [F-18]RGD-K5 F/U scan after 2 doses of bevacizumab, and another [F-18]RGD-K5 and [F-18] FDG F/U after 4 doses of bevacizumab. Many lesions in Subject-1 showed a high [F-18]RGD-K5 baseline uptake. The two most [F-18]RGD-K5 avid lesions had SUVs of 10.8 and 10.1, and the corresponding [F-18]FDG uptakes were much lower (SUV of 1.0 and 3.5). The [F-18]RGD-K5 SUVs in all analyzed lesions decreased during treatment, showi.. Read More»
  DOI: 10.4172/2155-9937.1000116

  Abstract PDF

Relevant Topics